CEO, Martin Jönsson at Redeye Theme Event Neurology, dec 3 2024
AlzeCure’s CEO Martin Jönsson presented at Aktiespararnas Stora Aktiedagarna in Stockholm November 27, 2024. (Swedish)
CEO Martin Jönsson at Finwire – About the progress and in the future in Alzheimer’s and pain. November 11, 2024 (Swedish)
The Presentation on the NeuroRestore ACD856 publication: “Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease” by Pontus Forsell et al from 2024, published in Pharmaceuticals (2024; 17(8), 997
ACD440 – A novel non-opioid analgesic, med Märta Segerdahl, CMO and project manager – AlzeCures live-event. 23 oktober, 2024
ACD440 – A novel non-opioid analgesic, med Dr. Rolf Karlsten – AlzeCures live-event. 23 oktober, 2024
ACD440 – A novel non-opioid analgesic – AlzeCures live-event. 23 oktober, 2024
CEO, Martin Jönsson to presented at Redeye’s Neurology Day, Presentation about AlzeCure, our Alzheimer and pain platforms, projects, etc. October 23, 2024
Presentation about AlzeCure by CEO Martin Jönsson, presented at LSX Nordic Congress, 8-9 October 2024
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish)
AlzeCures CEO, Martin Jönsson at Finwire (Swedish ) August 27, 2024
Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish)
CEO Martin Jönsson presents at Redeye Investor forum, May 16, 2024 (Swedish)
Interview at Redeye with CEO, Martin Jönsson,6 May 2024 (Swedish)
Rights issue presentation with CEO Martin Jönsson, May 2, 2024 (Swedish)
Interview at Finwire with Johan Sandin, CSO, 2 maj 2024 (Swedish)
SITDOWN at Finwire – AlzeCures CEO, Martin Jönsson about the rights issue, 2 May 2024 (Swedish)
AlzeCure’s CEO Martin Jönsson at Redeye, April 11, 2024 (Swedish)
CEO Martin Jönsson presenting at Finwire, April 10, 2024 (Swedish)
About Professor Jan Lundberg, who is proposed for election to the company’s Board of Directors
– from senior positions in global pharmaceutical companies, including global head of research at Astra and AstraZeneca and global R&D at Eli Lilly
AlzeCure’s CEO Martin Jönsson at Redeye’s event on Alzheimer’s, March 21, 2024 (Swedish)
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event – Alzheimer’s around highly current gamma-secretase modulators
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
Expert Event – Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together with professor Henrik Zetterberg”
AlzeCure at Redeye Life Science Day 2023 on November 23, 2023
AlzeCure at Redeye Neurology Theme Event October 11, 2023
AlzeCure Pharma present at Finwire September 5, 2023
AlzeCure Pharma present at Finwire – CMO Märta Segerdahl
AlzeCure Pharma present at Finwire – CSO Johan Sandin
AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023
AlzeCure Pharma – Capital Market Day May 17th, 2023
AlzeCure presents at Redeye Growth Day on June 1st, 2023
Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet
Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore
Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin
NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell
Interview at Finwire with CEO Martin Jönsson
CEO Martin Jönsson at Redeye April 12, 2023 (Swedish)
CEO Martin Jönsson participated in Redeye Alzheimer Seminar(Swedish)
Sitdown at Finwire with CEO Martin Jönsson(Swedish)
Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. January 31, 2023 (Swedish)
CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
Chief Scientific Officer Johan Sandin has participated in interview with Erik Penser Bank, December 13, 2022
(The presentation will be held in Swedish)
Interview at Finwire news with CEO Martin Jönsson, December 12, 2022
(The presentation will be held in Swedish)